Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A retrospective study on orelabrutinib combined with anti-CD20 monoclonal antibody regimen in treating mucosa-associated lymphoid tissue lymphoma.

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHongyong ZhangYWYingying Wu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows 100% objective response rate with orelabrutinib and anti-CD20 therapy in MALT lymphoma, indicating strong efficacy.

Key Points

  • This study evaluates the effectiveness and safety of orelabrutinib combined with anti-CD20 monoclonal antibody in treating mucosa-associated lymphoid tissue lymphoma.
  • Retrospective analysis of MALT lymphoma patients at Union Hospital, Tongji Medical College.
  • Patients received orelabrutinib and anti-CD20 monoclonal antibody regimen.
  • Efficacy measured by PET-CT/CT imaging and gastrointestinal endoscopy results.
  • 100% objective response rate observed in the cohort.
  • 75% complete response rate with varied responses in gastric and non-gastric subtypes.
  • Adverse events observed in 25% of cases, including hematological issues.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d717https://doi.org/10.1182/blood-2025-7130
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations
  2. 2Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma2025
  3. 3Efficacy, safety, and genetic analysis of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.2026
  4. 4Orelabrutinib with anti-CD20 monoclonal antibodies is highly effective and well-tolerated as first-line therapy for marginal zone lymphoma2026 · 1 citations
  5. 5Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma2025